PDS Biotechnology Regains Nasdaq Compliance, Eliminating Delisting Risk
PDSB has more than doubled off its 52-week low of $0.507.
Summary
PDS Biotechnology has officially regained compliance with Nasdaq's minimum $1.00 bid price requirement, removing the risk of delisting. This follows a deficiency notice issued on February 25, 2026, and an 8-K filing earlier today confirming the resolution. For a company of this size, maintaining Nasdaq listing is crucial for investor confidence and access to capital markets.
At the time of this announcement, PDSB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $66.4M. The 52-week trading range was $0.51 to $1.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.